Arcellx
Intelligent and adaptive cell therapies to treat the complexity of human disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $200m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | (2 %) | (47 %) | 123 % | 84 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (58 %) | (92 %) | (443 %) | (116 %) | (60 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (64 %) | (99 %) | (407 %) | (162 %) | (74 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 121 % | 146 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Arcellx is a clinical-stage biotechnology company focused on developing innovative immunotherapies to transform cell therapy. The company operates in the biopharmaceutical sector, targeting diseases that can be treated through advanced cell therapy techniques. Arcellx's primary clients include healthcare providers, research institutions, and patients in need of cutting-edge treatments for serious conditions. The business model revolves around the research, development, and commercialization of proprietary immunotherapy products. Revenue is generated through partnerships, licensing agreements, and eventual product sales upon regulatory approval. Arcellx aims to address unmet medical needs by leveraging its expertise in cell therapy to create effective and safe treatment options.
Keywords: biotechnology, immunotherapy, cell therapy, clinical-stage, biopharmaceutical, healthcare, research, development, commercialization, treatment